AZN Jun 2023 80.000 put
| Previous Close | 7.00 |
| Open | 7.00 |
| Bid | 6.95 |
| Ask | 7.10 |
| Strike | 80.00 |
| Expire Date | 2023-06-16 |
| Day's Range | 7.00 - 7.00 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
ZacksFDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
Following FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first PARP inhibitor approved in combination with a new hormonal agent in mCRPC.
ZacksIonis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
ZacksPharma Stock Roundup: FDA Okays PFE RSV Jab for Elderly, AZN Ends Brazikumab Studies
FDA approves Pfizer's (PFE) RSV vaccine for older adults and AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated metastatic castration-resistant prostate cancer
ZacksHere's Why Astrazeneca (AZN) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Motley Fool3 Nasdaq 100 Stocks That Are Surefire Buys in June
These phenomenal businesses have the tools and intangibles to make patient shareholders a lot richer.
ZacksAstraZeneca (AZN) Discontinues Brazikumab Development
AstraZeneca (AZN) announces its decision to discontinue the development of brazikumab for all indications under its inflammatory bowel disease program.
Business WireLYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer
WILMINGTON, Del., June 01, 2023--AstraZeneca and Merck & Co., Inc’s, known as MSD outside the US and Canada, LYNPARZA® (olaparib) in combination with abiraterone and prednisone or prednisolone has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
- Reuters
UPDATE 1-AstraZeneca to stop developing Crohn's disease drug
British drugmaker AstraZeneca said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis. The company said the discontinuation was due to a delay in the drug's development timeline, affected by global events and "the context of a competitive landscape". AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie's $63 billion tie-up with Allergan.
- Zacks
AstraZeneca (AZN) Drug Combo Meets Endometrial Cancer Study Goal
AstraZeneca (AZN) reports statistically significant results from a late-stage study evaluating the combination of Imfinzi and Lynparza in patients with advanced endometrial cancer.
Motley FoolWant to Grow Richer? These Stocks Have Doubled in the Past 5 Years
Shares of AstraZeneca (NASDAQ: AZN) and Merck (NYSE: MRK) have both more than doubled over the last five years. With a $228 billion market capitalization, AstraZeneca is the sixth-largest pharmaceutical company in the world and the second-biggest international-based drugmaker behind Novartis (NYSE: NVS). As you'd guess would be the case for a major player in the pharmaceutical industry, the British drugmaker possesses a remarkable product portfolio.
Business WireIMFINZI® (durvalumab) plus LYNPARZA® (olaparib) and IMFINZI alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
WILMINGTON, Del., May 26, 2023--Positive high-level results from the DUO-E Phase III trial showed IMFINZI® (durvalumab) in combination with platinum-based chemotherapy followed by either IMFINZI plus LYNPARZA® (olaparib) or IMFINZI alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy alone in patients with newly diagnosed advanced or recurrent endometrial cance
Business WireAstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
WILMINGTON, Del., May 25, 2023--AstraZeneca advances its ambition to revolutionize cancer care with new data across its industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 to 6, 2023.
Business WireNew AstraZeneca Data Presented at ATS 2023 Strengthen the Body of Evidence Supporting Early Intervention With BREZTRI in COPD
WILMINGTON, Del., May 23, 2023--Results from the EROS real-world retrospective study showed that initiating fixed-dose triple-combination therapy BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate) within 30 days of a qualifying moderate or severe exacerbation in patients with COPD (chronic obstructive pulmonary disease) is associated with a decreased risk of future exacerbations by 24% vs. delaying treatment by one to six months, and by 34% vs. delaying treatment six months to o
ZacksWhy Astrazeneca (AZN) is a Great Dividend Stock Right Now
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
ReutersAstraZeneca's China boss says drugmaker will seek to 'love the Communist Party'
Global drugmaker AstraZeneca will seek to be a patriotic company in China that "loves the Communist Party", its China president said at an event on Friday. Wang Lei, who is also the company's global executive vice president, made the comments at an event in the eastern city of Wuxi which the firm organised to celebrate its 30th year in China, according to a person familiar with the matter and photos shared with Reuters. While many local companies have in recent years publicly pledged allegiance to the ruling Chinese Communist Party as President Xi Jinping strengthened the party's role throughout Chinese society and its economy, such messaging is still unusual from foreign companies.
Business WireTAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial
WILMINGTON, Del., May 17, 2023--Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to TAGRISSO alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).
- Reuters
AstraZeneca's Tagrisso, chemo combination shows promise in lung cancer trial
The combination of AstraZeneca's cancer drug, Tagrisso, with chemotherapy to treat patients with a type of lung cancer showed positive results in a late-stage trial, the company said on Wednesday. The drug maker said patients on the combined treatment showed a meaningful improvement in progression-free survival, or how long a patient lives without the disease getting worse after treatment, than patients given only Tagrisso. The trial was on patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
- Reuters
UPDATE 1-AstraZeneca to leave leading U.S. drug lobby group
AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said. AstraZeneca decided not to continue its membership after a recent assessment of whether it was "the most productive and effective use of (company) resources", a spokesperson for the British drugmaker said in an emailed statement. PhRMA said in a separate emailed statement that AstraZeneca had decided not to renew its membership for the second half of 2023.
ReutersAstraZeneca to leave leading U.S. drug lobby group
LONDON (Reuters) -AstraZeneca has decided to leave the main U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), and pursue other ways of engaging in advocacy at the state and federal level, the company said. AstraZeneca decided not to continue its membership after a recent assessment of whether it was "the most productive and effective use of (company) resources", a spokesperson for the British drugmaker said in an emailed statement. PhRMA said in a separate emailed statement that AstraZeneca had decided not to renew its membership for the second half of 2023.
Simply Wall St.AstraZeneca PLC (LON:AZN) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?
AstraZeneca's (LON:AZN) stock is up by 4.2% over the past three months. However, the company's financials look a bit...
Motley FoolIs AstraZeneca Stock a Buy for Growth Investors?
Just 14% of drugs in development (according to a 2018 study) ever make it to market, so investing in pharmaceuticals is a bit of a shot in the dark. This is why I'd advise most investors to consider only the most dominant and established pharmaceutical companies for their portfolios. British drugmaker AstraZeneca (NASDAQ: AZN) is one such company.
- Zacks
Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates
Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.
Business WireFARXIGA extended in the US to reduce risk of cardiovascular death and hospitalization for heart failure to a broader range of patients
WILMINGTON, Del., May 09, 2023--AstraZeneca’s FARXIGA (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalization for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA) was based on positive results from the DELIVER Phase III trial.1 FARXIGA was previously approved in the US for adults with HF with reduced ejection fraction (HFrEF).
- Thomson Reuters StreetEvents
Q1 2023 Ionis Pharmaceuticals Inc Earnings Call
Q1 2023 Ionis Pharmaceuticals Inc Earnings Call
ZacksWhy Astrazeneca (AZN) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
